

WORKSHOP 1:

From the Research Result to the Product Exploitation

Short Description:

The main objective of this workshop is to present the services to FORTH Researchers of the two Units: PRAXI Network and Science & Technology Park of Crete (STEP-C) with respect to technology transfer, patent development process, exploitation of research results, spin-off company creating process and hosting/supporting in the starting period. Furthermore, innovators and co-founders of FORTH spin-off companies will also present their companies as successful examples of this process, and contribute their experience and suggestions for new/enhanced services for FORTH Researchers and companies.

Panelists:

Kostas Vavekis, Director, PRAXI NETWORK

George Papamichail, Director, Science & Technology Park of Crete (STEP-C)

Electra Gizeli, Deputy Director IMBB, Professor Dept. of Biology, U. of Crete, Co-Founder BIOPIX DNA TECHNOLOGY (GR) and AWSensors Dx (ES)

Panos Trahanias, CRO & Co-founder of ORamaVR, Collaborating Faculty Member and Lab Head at ICS, Professor of Computer Science, U. of Crete

Nikolaos Kyriazis, Co-Founder of SceneOpsis

Giannis Zacharakis, Principal Researcher IESL, Co-founder and CEO of KYMATONICS

Achilleas Gravanis (via zoom), Co-founder & CEO of ReNeurocell Therapeutics/ co-founder & BoD Member of BioNature, coll. faculty member IMBB, Professor of Pharmacology, Medical School, U. of Crete

Short Descriptions of the Presented Spin-offs

- **ORamaVR SA** (<https://oramavr.com/>) is a spin-off of FORTH Institute of Computer Science, accelerating the world's transition to medical XR through spatial computing and spatial intelligence. Our platform, the MAGES-SUITE, an AI-powered, low/no-code software, enables rapid creation and deployment of high-fidelity medical XR simulations and is clinically proven to deliver 32% medical skill gain, 80% error reduction in surgical, diagnostics, therapeutics.
- **SceneOpsis** (<https://sceneopsis.com/>) is a spin-off from CVRL/FORTH specializing in computer vision and artificial intelligence. Our mission is to democratize the creation of immersive 3D experiences by enabling users to quickly capture true-to-life virtual tours of living and working spaces using just a smartphone. With applications spanning real estate, hospitality, art & culture, and beyond, SceneOpsis transforms

spaces into as-if-there digital experiences that are shareable and accessible from any device.

- **Kymatonics** (<https://kymatonics.com>) is a SPIN-OFF of FORTH/IESL. Its expertise is in developing optical solutions for smart and precise light control. Kymatonics was established to exploit and commercialize the Wavelens innovative device: a wavefront shaping digital microscope lens and explore appropriate use cases and disruptive market applications.
- **ReNeurocell Therapeutics** (<https://www.reneurocell.com/>) has developed a neuroimplant that it licenses to US company NeuroCord for its clinical application against spinal cord injury and paralysis. The neuroimplant consists of a 3D scaffold of advanced biomaterials that host human neural stem cells.
- **BioNature** (<https://www.bionature.net>) has developed small synthetic molecules, agonists of Neurotrophin receptors with strong neuroprotective and neuroregenerative effects. The BNN27 molecule has been licensed to the European company Novaliq for its clinical application in diabetic retinopathy. Both therapeutics are the first Greek prototypes that are headed for international clinical trials.